This is the federal position checked on 28 October 2026. State law, the patient’s insurance, the service and the clinician’s authorization can still change what is available in an individual case. The dates below replace the 2025 deadlines in the earlier version of this article.
Medicare access is extended through 2027
The HHS telehealth policy update explains that many Medicare flexibilities continue through 31 December 2027. These include home access without geographic restrictions for non-behavioral services and an expanded range of eligible practitioners. It also describes audio-only options and rules for federally qualified health centres and rural health clinics.
This is an extension of specified rules, not a promise that every remote service is covered in every setting. The Medicare coverage page explains the benefit and notes that costs and available benefits can differ by plan and circumstances. A patient should confirm the particular appointment and charge with the provider and insurer rather than infer coverage from the word telehealth.
Behavioral health has permanent and temporary elements
HHS lists permanent home access and removal of geographic restrictions for Medicare behavioral and mental health telehealth. It separately lists the delay of specified in-person-visit requirements through 31 December 2027. These are different provisions: calling the category permanent must not erase a visit requirement with its own timetable.
Remote mental-health coverage is also a different question from eligibility for an in-person community programme. Our account of New York’s clubhouse expansion explains who that programme serves and which planned outcomes remain to be evaluated.
The same distinction matters for audio-only care. A policy allowing a telephone encounter in an eligible circumstance does not establish that a telephone call can replace every examination or procedure. Clinical appropriateness remains a separate question from whether the communication method can qualify for payment.
Controlled-medication prescribing has a 2026 deadline
A joint HHS and DEA announcement describes the fourth temporary extension, from 1 January through 31 December 2026, of specified telemedicine prescribing flexibilities without a prior in-person visit. Prescriptions must still have a legitimate medical purpose and comply with applicable federal and state requirements.
That extension is not permission for any clinician to prescribe any medicine through any app. Drug schedules, practitioner authorization and the type of encounter matter. The published temporary rule also distinguishes the extension from separate rules concerning buprenorphine and Veterans Affairs patients. A proposed future registration system should not be described as an already effective replacement.
Hospital at home is a different programme
The CMS Acute Hospital Care at Home programme concerns hospital-level inpatient care delivered at home under individual hospital waivers. Its current extension ends on 30 September 2030, absent further congressional action. CMS says it will stop accepting participation requests after 1 September 2030 and requires participating hospitals to report safety and quality data.
This is not simply a video appointment funded under the ordinary telehealth benefit. A hospital needs its own qualifying waiver; a health system’s participation does not automatically cover every hospital it owns. For a patient, the relevant questions include eligibility, monitoring, in-person support and the route back to a hospital if needed.
Federal payment rules do not create a nationwide licence
The HHS guide to licensing across state lines sets out routes such as a full licence, temporary practice rules, reciprocity, compacts and telehealth registration. Which route is available depends on the jurisdiction and profession. The patient’s location during an appointment is therefore information the provider needs to establish.
A useful check before booking is to ask four separate questions: is this service clinically suitable remotely, may this practitioner treat me where I am, will my plan cover it, and do any prescribing or in-person requirements apply? Keeping those questions separate is more reliable than labelling telemedicine as either fully permanent or about to disappear.
